Evidence map›Paper›PMID 29187159›Full record

ArticleBMC infectious diseases2017

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.

Chris Verhofstede, Katrien Fransen, Annelies Van Den Heuvel, Kristel Van Laethem, Jean Ruelle, Ellen Vancutsem, Karolien Stoffels, Sigi Van den Wijngaert, Marie-Luce Delforge, Dolores Vaira and 5 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chris VerhofstedeAids Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. chris.verhofstede@ugent.be.ORCID 0000-0002-0645-1174
Katrien FransenHIV/STD Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Annelies Van Den HeuvelHIV/STD Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Kristel Van LaethemDepartment of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven - University of Leuven, Leuven, Belgium.
Jean RuelleAids Reference Laboratory, Medical Microbiology unit, Université Catholique de Louvain, Brussels, Belgium.
Ellen VancutsemAids Reference Laboratory, Vrije Universiteit Brussel VUB, Brussels, Belgium.
Karolien StoffelsAids Reference Laboratory, Centre Hospitalier Universitaire St. Pierre, Brussels, Belgium.
Sigi Van den WijngaertAids Reference Laboratory, Centre Hospitalier Universitaire St. Pierre, Brussels, Belgium.
Marie-Luce DelforgeAids Reference Laboratory, Université Libre de Bruxelles, Brussels, Belgium.
Dolores VairaAids Reference Laboratory, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
Laura HebberechtAids Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Marlies SchauvliegeAids Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Virginie MortierAids Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Kenny DauweAids Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Steven CallensAids Reference Center and Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium.

Funding

Fonds voor Wetenschappelijk Onderzoek Vlaanderen FWO G.0692.14NKoning Boudewijnstichting 2013-J1820640-201099
6 · The paper itself

Abstract

backgroundThere is today no gold standard method to accurately define the time passed since infection at HIV diagnosis. Infection timing and incidence measurement is however essential to better monitor the dynamics of local epidemics and the effect of prevention initiatives.

methodsThree methods for infection timing were evaluated using 237 serial samples from documented seroconversions and 566 cross sectional samples from newly diagnosed patients: identification of antibodies against the HIV p31 protein in INNO-LIA, SediaTM BED CEIA and SediaTM LAg-Avidity EIA. A multi-assay decision tree for infection timing was developed.

resultsClear differences in recency window between BED CEIA, LAg-Avidity EIA and p31 antibody presence were observed with a switch from recent to long term infection a median of 169.5, 108.0 and 64.5 days after collection of the pre-seroconversion sample respectively. BED showed high reliability for identification of long term infections while LAg-Avidity is highly accurate for identification of recent infections. Using BED as initial assay to identify the long term infections and LAg-Avidity as a confirmatory assay for those classified as recent infection by BED, explores the strengths of both while reduces the workload. The short recency window of p31 antibodies allows to discriminate very early from early infections based on this marker. BED recent infection results not confirmed by LAg-Avidity are considered to reflect a period more distant from the infection time. False recency predictions in this group can be minimized by elimination of patients with a CD4 count of less than 100 cells/mm3 or without no p31 antibodies. For 566 cross sectional sample the outcome of the decision tree confirmed the infection timing based on the results of all 3 markers but reduced the overall cost from 13.2 USD to 5.2 USD per sample.

conclusionsA step-wise multi assay decision tree allows accurate timing of the HIV infection at diagnosis at affordable effort and cost and can be an important new tool in studies analyzing the dynamics of local epidemics or the effects of prevention strategies.

Indexed as

Decision TreesAdultBelgiumCD4 Lymphocyte CountCross-Sectional StudiesFemaleHIV-1HIV AntigensHIV InfectionsHIV SeropositivityHumansIncidenceLongitudinal StudiesMaleMiddle AgedReproducibility of ResultsHIV-1 protein p31, Human immunodeficiency virus 1HIV AntigensHIVIncidence measurementInfection timing

Identifiers

PMID29187159
PMCPMC5708102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.